333 related articles for article (PubMed ID: 36766776)
1. RHOA Therapeutic Targeting in Hematological Cancers.
Santos JC; Profitós-Pelejà N; Sánchez-Vinces S; Roué G
Cells; 2023 Jan; 12(3):. PubMed ID: 36766776
[TBL] [Abstract][Full Text] [Related]
2. RAS and RHO family GTPase mutations in cancer: twin sons of different mothers?
Hodge RG; Schaefer A; Howard SV; Der CJ
Crit Rev Biochem Mol Biol; 2020 Aug; 55(4):386-407. PubMed ID: 32838579
[TBL] [Abstract][Full Text] [Related]
3. Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells.
O'Hayre M; Inoue A; Kufareva I; Wang Z; Mikelis CM; Drummond RA; Avino S; Finkel K; Kalim KW; DiPasquale G; Guo F; Aoki J; Zheng Y; Lionakis MS; Molinolo AA; Gutkind JS
Oncogene; 2016 Jul; 35(29):3771-80. PubMed ID: 26616858
[TBL] [Abstract][Full Text] [Related]
4. Variegated RHOA mutations in human cancers.
Kataoka K; Ogawa S
Exp Hematol; 2016 Dec; 44(12):1123-1129. PubMed ID: 27693615
[TBL] [Abstract][Full Text] [Related]
5. Cell type-specific signaling function of RhoA GTPase: lessons from mouse gene targeting.
Zhou X; Zheng Y
J Biol Chem; 2013 Dec; 288(51):36179-88. PubMed ID: 24202176
[TBL] [Abstract][Full Text] [Related]
6. Reduced RhoA expression enhances breast cancer metastasis with a concomitant increase in CCR5 and CXCR4 chemokines signaling.
Kalpana G; Figy C; Yeung M; Yeung KC
Sci Rep; 2019 Nov; 9(1):16351. PubMed ID: 31705019
[TBL] [Abstract][Full Text] [Related]
7. Novel cardiovascular protective effects of RhoA signaling and its therapeutic implications.
Soh JEC; Shimizu A; Sato A; Ogita H
Biochem Pharmacol; 2023 Dec; 218():115899. PubMed ID: 37907138
[TBL] [Abstract][Full Text] [Related]
8. RhoA: a dubious molecule in cardiac pathophysiology.
Kilian LS; Voran J; Frank D; Rangrez AY
J Biomed Sci; 2021 Apr; 28(1):33. PubMed ID: 33906663
[TBL] [Abstract][Full Text] [Related]
9. Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer.
Chang HR; Nam S; Lee J; Kim JH; Jung HR; Park HS; Park S; Ahn YZ; Huh I; Balch C; Ku JL; Powis G; Park T; Jeong JH; Kim YH
Oncotarget; 2016 Dec; 7(49):81435-81451. PubMed ID: 27806312
[TBL] [Abstract][Full Text] [Related]
10. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
11. RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion.
Nguyen QD; Faivre S; Bruyneel E; Rivat C; Seto M; Endo T; Mareel M; Emami S; Gespach C
FASEB J; 2002 Apr; 16(6):565-76. PubMed ID: 11919159
[TBL] [Abstract][Full Text] [Related]
12. A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells.
Wang L; Yang L; Luo Y; Zheng Y
J Biol Chem; 2003 Nov; 278(45):44617-25. PubMed ID: 12939257
[TBL] [Abstract][Full Text] [Related]
13. RhoA Signaling in Neurodegenerative Diseases.
Schmidt SI; Blaabjerg M; Freude K; Meyer M
Cells; 2022 May; 11(9):. PubMed ID: 35563826
[TBL] [Abstract][Full Text] [Related]
14. Gain-of-Function
Zhang H; Schaefer A; Wang Y; Hodge RG; Blake DR; Diehl JN; Papageorge AG; Stachler MD; Liao J; Zhou J; Wu Z; Akarca FG; de Klerk LK; Derks S; Pierobon M; Hoadley KA; Wang TC; Church G; Wong KK; Petricoin EF; Cox AD; Lowy DR; Der CJ; Bass AJ
Cancer Discov; 2020 Feb; 10(2):288-305. PubMed ID: 31771969
[TBL] [Abstract][Full Text] [Related]
15. Optogenetic control of small GTPases reveals RhoA mediates intracellular calcium signaling.
Inaba H; Miao Q; Nakata T
J Biol Chem; 2021; 296():100290. PubMed ID: 33453281
[TBL] [Abstract][Full Text] [Related]
16. RHOA takes the RHOad less traveled to cancer.
Schaefer A; Der CJ
Trends Cancer; 2022 Aug; 8(8):655-669. PubMed ID: 35568648
[TBL] [Abstract][Full Text] [Related]
17. Rho isoform-specific interaction with IQGAP1 promotes breast cancer cell proliferation and migration.
Casteel DE; Turner S; Schwappacher R; Rangaswami H; Su-Yuo J; Zhuang S; Boss GR; Pilz RB
J Biol Chem; 2012 Nov; 287(45):38367-78. PubMed ID: 22992742
[TBL] [Abstract][Full Text] [Related]
18. Variegated RHOA mutations in adult T-cell leukemia/lymphoma.
Nagata Y; Kontani K; Enami T; Kataoka K; Ishii R; Totoki Y; Kataoka TR; Hirata M; Aoki K; Nakano K; Kitanaka A; Sakata-Yanagimoto M; Egami S; Shiraishi Y; Chiba K; Tanaka H; Shiozawa Y; Yoshizato T; Suzuki H; Kon A; Yoshida K; Sato Y; Sato-Otsubo A; Sanada M; Munakata W; Nakamura H; Hama N; Miyano S; Nureki O; Shibata T; Haga H; Shimoda K; Katada T; Chiba S; Watanabe T; Ogawa S
Blood; 2016 Feb; 127(5):596-604. PubMed ID: 26574607
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of miR-345-5p suppresses cell growth of lung adenocarcinoma by regulating ras homolog family member A (RhoA) and Rho/Rho associated protein kinase (Rho/ROCK) pathway.
Zhou QY; Gui SY; Zhang P; Wang M
Chin Med J (Engl); 2021 Oct; 134(21):2619-2628. PubMed ID: 34748526
[TBL] [Abstract][Full Text] [Related]
20. Negative regulation of RhoA translation and signaling by hnRNP-Q1 affects cellular morphogenesis.
Xing L; Yao X; Williams KR; Bassell GJ
Mol Biol Cell; 2012 Apr; 23(8):1500-9. PubMed ID: 22357624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
